Financials in USD. Standardized financial statements.
A compact view of how C4 Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $35.95M | $35.58M | $20.76M | $31.10M | $45.78M | $33.20M | $21.38M | $19.36M |
| Revenue Growth? | +1.0% | +71.4% | -33.3% | -32.1% | +37.9% | +55.3% | +10.4% | 0.0% |
| Cost of Revenue? | $7.97M | $0 | $7.74M | $0 | $0 | $78.44M | $0 | $28.59M |
| Gross Profit? | $27.97M | $35.58M | $13.02M | $31.10M | $45.78M | -$45.24M | $21.38M | -$9.23M |
| Gross Margin? | +77.8% | +100.0% | +62.7% | +100.0% | +100.0% | -136.3% | +100.0% | -47.7% |
| Operating Expenses? | $132.46M | $155.20M | $152.05M | $160.63M | $127.92M | $15.20M | $56.83M | $35.75M |
| Operating Income? | -$104.49M | -$119.61M | -$139.03M | -$129.53M | -$82.13M | -$60.45M | -$35.45M | -$16.39M |
| EBITDA? | -$102.91M | -$103.37M | -$122.10M | -$124.28M | -$80.25M | -$58.83M | -$31.70M | -$15.12M |
| Income Before Tax | -$104.87M | -$105.19M | -$131.21M | -$128.18M | -$83.89M | -$65.71M | -$33.30M | -$15.71M |
| Income Tax Expense | $121,000 | $131,000 | $1.28M | $0 | $0 | $626,000 | $804,000 | $0 |
| Net Income? | -$104.99M | -$105.32M | -$132.49M | -$128.18M | -$83.89M | -$66.33M | -$34.10M | -$15.71M |
| EPS? | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 | $-1.54 | $-0.79 | $-1.06 |
| Diluted EPS? | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 | $-1.54 | $-0.79 | $-1.06 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality